Keyword: Novartis

News

India Revokes GSK Cancer Drug Patent In Latest Big Pharma Blow

05.08.2013 - India has revoked a patent granted to GlaxoSmithKline for breast cancer drug Tykerb, a decision that follows a landmark India court ruling disallowing patents for incremental...

News

Europe Backs New Dual-Action Novartis Lung Drug

29.07.2013 - Swiss drugmaker Novartis won an important endorsement of its new inhaled medicine for chronic lung disease on Friday when European regulators recommended approval of Ultibro...

News

Bexsero Setback hits Novartis’ Vaccine Division

25.07.2013 - Swiss drug maker Novartis suffered a fresh blow to the turnaround prospects of its loss-making vaccines division as a key committee advised against including its meningitis B...

News

GSK Says Executives Appear To Have Broken Chinese law

22.07.2013 - British drugmaker GlaxoSmithKline said on Monday some of its executives in China appeared to have broken the law in a bribery scandal, as it promised changes in its business model...

News

China Blocks GSK Finance Head From Leaving Country

18.07.2013 - Chinese authorities investigating the alleged bribery of doctors and officials by GlaxoSmithKline have stopped the drugmaker's head of finance for China, a British citizen, from...

News

Novartis Lifts Full-Year Outlook After Competition Delay

18.07.2013 - Novartis raised its full-year outlook on Wednesday after generic competition to its best-selling blood pressure pill was delayed, granting the Swiss drugmaker a temporary reprieve...

News

Abbott to Buy OptiMedica, Strengthens Medical Device Focus

16.07.2013 - Abbott said on Monday that it would enter the laser cataract surgery business by buying privately held OptiMedica for up to $400 million and in a separate deal would pay $310...

News

Pfizer, Novartis May Join Amgen in Bidding for Onyx

02.07.2013 - Onyx Pharmaceuticals, whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer and...